

**Company Announcement**

No. 28/2015

## **Zealand increases its share capital after exercise of employee warrants**

*Copenhagen, 20 June 2015* – Zealand Pharma (“Zealand”) (Nasdaq Copenhagen: ZEAL) announces that its share capital has been increased by nominal DKK 46,521 divided into 46,521 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of employee warrants granted under three of the company’s warrant programs as described in the Articles of Association.

The exercise price is DKK 94.60 per share for 33,506 of the new shares of nominal DKK 1 and DKK 77.00 per share for 13,015 of the new shares of nominal DKK 1. The total proceeds to Zealand from the capital increase amounts to DKK 4,171,822.60.

Each new share of nominal DKK 1 carries one vote at Zealand’s general meetings. The new shares give rights to dividend and other rights from the time of the warrant holder’s exercise notice. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen following registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 23,518,108 divided into 23,518,108 shares with a nominal value of DKK 1 each.

The content of this announcement has no impact on the company’s financial outlook for 2015.



**For further information, please contact:**

Hanne Leth Hillman, Senior Vice President, Investor Relations & Communications  
Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)

**About Zealand Pharma**

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and is in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for Lyxumia® is planned for Q3 2015 and filing for LixiLan is planned for Q4 2015 in the US and Q1 2016 in Europe.

Zealand’s proprietary pipeline include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable



glucagon analogue, ZP4207 in two Phase I trials as a single-use rescue pen (severe hypoglycemia) and a multiple-dose version (mild to moderate hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company's products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

For further information: [www.zealandpharma.com](http://www.zealandpharma.com) Follow us on Twitter @ZealandPharma